This week, BioSpectrum Asia reported the news of Daewoong Pharmaceutical Co., Ltd. and HanAll BioPharma Co., Ltd.’s investment in Alloplex Biotherapeutics, Inc. this week. Here is a copy of that coverage.
Daewoong Pharma, Hanall Biopharma invest $1M for new cancer cell therapies
Daewoong Pharmaceutical and Hanall Biopharma of South Korea are expanding their global open collaboration initiative by investing in Alloplex Biotherapeutics, an emerging Boston-based biotechnology company.
Daewoong Pharmaceutical and Hanall Biopharma have announced their investment in Alloplex Biotherapeutics by purchasing to support a potential long-term collaboration for developing new cancer cell therapies. Daewoong Pharmaceutical and Hanall Biopharma aim to collaborate with Alloplex to develop global networks and communication with experts in this domain…
Continue to read the full article:
PR newswire release:
To request interviews, high res images or other materials, media are asked to:
Email: media@alloplexbio.com
Attn: Lesley White, Alloplex Australia
For media requests on deadline during USA Eastern hours, please call: +1-781-281-2013
